文献速递肿瘤 PET/CT核素与放射性配体治疗

用68Ga-DOTATOC PET/CT的变异系数评估神经内分泌肿瘤患者SSTR2表达异质性

Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors.
PubMed 文献 · J Nucl Med · 2022-03-10

研究纳入38例病理证实的神经内分泌肿瘤患者,行68Ga-DOTATOC PET/CT,用变异系数(CoV)量化原发灶与转移灶SSTR2表达异质性。共分析107个病灶,恶性病灶CoV最高达正常组织4倍(P≤0.0001);骨转移CoV最高(0.68±0.20),肝转移最低(0.32±0.07)。作者认为摄取异质性随病灶类型和部位而异,可能影响生长抑素类似物治疗反应。

要点

  • 恶性病灶CoV最高达正常组织4倍(P≤0.0001),骨转移CoV 0.68±0.20显著高于原发灶(P=0.01)和肝转移(P<0.0001)。
  • 原发灶平均CoV 0.49±0.20,淋巴结转移0.57±0.26,远处转移0.44±0.20。
  • 肝病灶CoV最低(0.32±0.07),作者认为可能与肝背景摄取高有关。

核心结论

  • 68Ga-DOTATOC PET/CT所得CoV显示,反映SSTR2表达的摄取异质性随恶性病灶类型和部位而异。
  • 作者认为这些观察可能与同一患者不同肿瘤病灶的生物学特征差异有关,并可能影响其对标记或未标记生长抑素类似物治疗的反应。

研究设计与样本

  • 研究纳入38例病理证实的神经内分泌肿瘤患者,均行68Ga-DOTATOC PET/CT。
  • 原发肿瘤位于胃肠胰、支气管肺和其他解剖区域者分别为25例、7例和6例。
  • 恶性病灶用自动勾画程序分割,SUV阈值大于2.5,肝病灶采用SUVmax的30%为阈值。
  • 每个病灶获取SUVmean、CoV、SUVmax、受体表达肿瘤体积和总病灶受体表达;正常肝、脾代表性体积及整个垂体也获取SUVmean、CoV和SUVmax。

主要发现

  • 共分析107个病灶,包括35个原发肿瘤、32个转移淋巴结和40个远处转移。
  • 原发肿瘤平均CoV为0.49±0.20,淋巴结转移为0.57±0.26,远处转移为0.44±0.20。
  • 恶性病灶CoV最高达正常组织的4倍(P≤0.0001)。
  • 恶性病灶中骨转移CoV最高(0.68±0.20),显著高于原发灶(P=0.01)和肝转移(P<0.0001)。
  • 肝病灶CoV最低(0.32±0.07),作者认为可能与肝背景摄取高有关。

关键数值与推荐

  • 恶性病灶分割采用SUV>2.5阈值,肝病灶采用SUVmax的30%阈值。
  • 原发肿瘤CoV 0.49±0.20,淋巴结转移0.57±0.26,远处转移0.44±0.20。
  • 骨转移CoV 0.68±0.20,高于原发灶(P=0.01)和肝转移(P<0.0001)。
  • 肝病灶CoV 0.32±0.07。
  • 恶性病灶CoV最高达正常组织4倍(P≤0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High levels of somatostatin receptor subtype 2 (SSTR2) are a prerequisite for therapy with unlabeled or labeled somatostatin analogs. However, it is still unclear how the heterogeneity of SSTR2 expression may affect tumor response to therapy. The aim of our study was to test the ability of an imaging parameter such as coefficient of variation (CoV) derived from PET/CT with 68Ga-peptides in the evaluation and quantification of the heterogeneity of SSTR2 expression within primary and metastatic lesions of patients with neuroendocrine tumors. Methods: Thirty-eight patients with pathologically proven neuroendocrine tumors who underwent 68Ga-DOTATOC PET/CT were studied. Primary tumors were localized in the gastroenteropancreatic, bronchopulmonary, and other anatomic districts in 25, 7, and 6 patients, respectively. Malignant lesions were segmented using an automated contouring program and an SUV threshold of more than 2.5 or, in the case of liver lesions, a threshold of 30% of the SUVmax The imaging parameters SUVmean, CoV, SUVmax, receptor-expressing tumor volume, and total lesion receptor expression were obtained for each lesion. SUVmean, CoV, and SUVmax were also obtained for representative volumes of normal liver and spleen, as well as for the whole pituitary gland. Results: In total, 107 lesions were analyzed, including 35 primary tumors, 32 metastatic lymph nodes, and 40 distant metastases. Average CoVs were 0.49 ± 0.20 for primary tumors, 0.57 ± 0.26 for lymph node metastases, and 0.44 ± 0.20 for distant metastases. The CoVs of malignant lesions were up to 4-fold higher than those of normal tissues (P ≤ 0.0001). Among malignant lesions, the highest CoV was found for bone metastases (0.68 ± 0.20), and it was significantly greater than that of primary lesions (P = 0.01) and liver metastases (P < 0.0001). On the other hand, the lowest CoV was found for liver lesions (0.32 ± 0.07), probably because of the high background uptake. Conclusion: Our findings indicate that the heterogeneity of uptake, reflecting that of SSTR2, varies with the type and site of malignant lesions as assessed by CoVs obtained from 68Ga-DOTATOC PET/CT scans. These observations may be related to different biologic characteristics of tumor lesions in the same patient-differences that may affect their response to treatment with both labeled and unlabeled somatostatin analogs.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fonti R, Panico M, Pellegrino S, et al. Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors. J Nucl Med. 2022. PMID: 35273092. doi:10.2967/jnumed.121.262928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。